Transplant Trial Watch.
作者信息
Knight Simon R
机构信息
Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Oxford Transplant Centre, Churchill Hospital, Oxford, United Kingdom.
出版信息
Transpl Int. 2023 Dec 12;36:12423. doi: 10.3389/ti.2023.12423. eCollection 2023.
Abstract
摘要
相似文献
1
Transplant Trial Watch.移植试验观察
Transpl Int. 2023 Dec 12;36:12423. doi: 10.3389/ti.2023.12423. eCollection 2023.
2
Transplant Trial Watch.移植试验观察
Transpl Int. 2024 Jan 22;37:12597. doi: 10.3389/ti.2024.12597. eCollection 2024.
3
Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.他克莫司：其在器官移植管理中的药理学及治疗应用的进一步更新
Drugs. 2000 Feb;59(2):323-89. doi: 10.2165/00003495-200059020-00021.
4
Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.肝移植成年受者的维持性免疫抑制：一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Mar 31;3(3):CD011639. doi: 10.1002/14651858.CD011639.pub2.
5
Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.他克莫司与环孢素作为肺移植受者的初始免疫抑制治疗比较
Cochrane Database Syst Rev. 2013 May 31(5):CD008817. doi: 10.1002/14651858.CD008817.pub2.
6
The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.他克莫司与微乳化环孢素的成本效益：肾移植结局的10年模型
Pharmacoeconomics. 2003;21(17):1263-76. doi: 10.2165/00019053-200321170-00003.
7
Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review.确定他克莫司暴露与心肺移植受者毒性之间的关联：一项系统评价。
Transplant Rev (Orlando). 2021 Apr;35(2):100610. doi: 10.1016/j.trre.2021.100610. Epub 2021 Feb 27.
8
Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.创新型与仿制药他克莫司在肝肾移植受者中的生物等效性：一项随机交叉临床试验。
PLoS Med. 2017 Nov 14;14(11):e1002428. doi: 10.1371/journal.pmed.1002428. eCollection 2017 Nov.
9
Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.他克莫司与环孢素作为肾移植受者的初始免疫抑制治疗比较
Cochrane Database Syst Rev. 2005 Oct 19(4):CD003961. doi: 10.1002/14651858.CD003961.pub2.
10
Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.韩国实体器官移植受者中他克莫司浓度与CYP3A和ABCB1基因多态性的关系。
Transplantation. 2009 Apr 27;87(8):1225-31. doi: 10.1097/TP.0b013e31819f117e.
本文引用的文献
1
Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.肾移植中 2 种免疫抑制最小化策略的比较：ALLEGRO 试验。
Transplantation. 2024 Feb 1;108(2):556-566. doi: 10.1097/TP.0000000000004776. Epub 2024 Jan 19.
2
Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.肾移植受者停用或减量钙调神经磷酸酶抑制剂
Cochrane Database Syst Rev. 2017 Jul 21;7(7):CD006750. doi: 10.1002/14651858.CD006750.pub2.
3
Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis.肾移植后避免或停用类固醇会增加急性排斥反应的风险，但会降低心血管风险。一项荟萃分析。
Transplantation. 2010 Jan 15;89(1):1-14. doi: 10.1097/TP.0b013e3181c518cc.
Zotero 插件